vs
雅培（ABT）与阿斯利康（AZN）财务数据对比。点击上方公司名可切换其他公司
阿斯利康的季度营收约是雅培的1.3倍（$14.5B vs $11.5B）。阿斯利康净利率更高（16.9% vs 15.5%，领先1.4%）。阿斯利康同比增速更快（11.7% vs 4.4%）
雅培是总部位于美国伊利诺伊州雅培园的跨国医疗健康企业，业务覆盖美国境外市场药品销售、诊断产品、营养产品及医疗器械等板块，在全球医疗健康领域拥有较高的行业知名度与广泛的市场覆盖。
阿斯利康是一家瑞典与英国合资的跨国制药及生物技术企业，总部位于英国剑桥的剑桥生物医学园区。公司产品管线覆盖肿瘤、心血管、消化、感染、神经科学、呼吸、炎症等重大疾病领域。
ABT vs AZN — 直观对比
营收规模更大
AZN
是对方的1.3倍
$11.5B
营收增速更快
AZN
高出7.3%
4.4%
净利率更高
AZN
高出1.4%
15.5%
损益表 — Q4 2025 vs Q2 2025
| 指标 | | |
|---|---|---|
| 营收 | $11.5B | $14.5B |
| 净利润 | $1.8B | $2.4B |
| 毛利率 | 57.0% | 82.9% |
| 营业利润率 | 19.6% | 24.3% |
| 净利率 | 15.5% | 16.9% |
| 营收同比 | 4.4% | 11.7% |
| 净利润同比 | -80.8% | 27.0% |
| 每股收益（稀释后） | $1.01 | $1.57 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABTAZN
| Q4 25 | $11.5B | — | ||
| Q3 25 | $11.4B | — | ||
| Q2 25 | $11.1B | $14.5B | ||
| Q1 25 | $10.4B | — | ||
| Q4 24 | $11.0B | — | ||
| Q3 24 | $10.6B | — | ||
| Q2 24 | $10.4B | $12.9B | ||
| Q1 24 | $10.0B | — |
净利润ABTAZN
| Q4 25 | $1.8B | — | ||
| Q3 25 | $1.6B | — | ||
| Q2 25 | $1.8B | $2.4B | ||
| Q1 25 | $1.3B | — | ||
| Q4 24 | $9.2B | — | ||
| Q3 24 | $1.6B | — | ||
| Q2 24 | $1.3B | $1.9B | ||
| Q1 24 | $1.2B | — |
毛利率ABTAZN
| Q4 25 | 57.0% | — | ||
| Q3 25 | 55.4% | — | ||
| Q2 25 | 56.4% | 82.9% | ||
| Q1 25 | 56.9% | — | ||
| Q4 24 | 55.0% | — | ||
| Q3 24 | 55.8% | — | ||
| Q2 24 | 55.6% | 83.1% | ||
| Q1 24 | 55.2% | — |
营业利润率ABTAZN
| Q4 25 | 19.6% | — | ||
| Q3 25 | 18.1% | — | ||
| Q2 25 | 18.4% | 24.3% | ||
| Q1 25 | 16.3% | — | ||
| Q4 24 | 17.4% | — | ||
| Q3 24 | 17.5% | — | ||
| Q2 24 | 16.1% | 21.2% | ||
| Q1 24 | 13.9% | — |
净利率ABTAZN
| Q4 25 | 15.5% | — | ||
| Q3 25 | 14.5% | — | ||
| Q2 25 | 16.0% | 16.9% | ||
| Q1 25 | 12.8% | — | ||
| Q4 24 | 84.1% | — | ||
| Q3 24 | 15.5% | — | ||
| Q2 24 | 12.5% | 14.9% | ||
| Q1 24 | 12.3% | — |
每股收益（稀释后）ABTAZN
| Q4 25 | $1.01 | — | ||
| Q3 25 | $0.94 | — | ||
| Q2 25 | $1.01 | $1.57 | ||
| Q1 25 | $0.76 | — | ||
| Q4 24 | $5.26 | — | ||
| Q3 24 | $0.94 | — | ||
| Q2 24 | $0.74 | $1.24 | ||
| Q1 24 | $0.70 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.9B | $7.1B |
| 总债务越低越好 | $12.9B | — |
| 股东权益账面价值 | $52.1B | $44.8B |
| 总资产 | $86.7B | $112.4B |
| 负债/权益比越低杠杆越低 | 0.25× | — |
8季度趋势，按日历期对齐
现金及短期投资ABTAZN
| Q4 25 | $8.9B | — | ||
| Q3 25 | $7.7B | — | ||
| Q2 25 | $7.3B | $7.1B | ||
| Q1 25 | $6.8B | — | ||
| Q4 24 | $8.0B | — | ||
| Q3 24 | $7.8B | — | ||
| Q2 24 | $7.2B | $6.9B | ||
| Q1 24 | $6.7B | — |
总债务ABTAZN
| Q4 25 | $12.9B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $14.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ABTAZN
| Q4 25 | $52.1B | — | ||
| Q3 25 | $51.0B | — | ||
| Q2 25 | $50.6B | $44.8B | ||
| Q1 25 | $48.8B | — | ||
| Q4 24 | $47.7B | — | ||
| Q3 24 | $39.8B | — | ||
| Q2 24 | $39.3B | $39.6B | ||
| Q1 24 | $38.8B | — |
总资产ABTAZN
| Q4 25 | $86.7B | — | ||
| Q3 25 | $84.2B | — | ||
| Q2 25 | $84.0B | $112.4B | ||
| Q1 25 | $81.4B | — | ||
| Q4 24 | $81.4B | — | ||
| Q3 24 | $74.4B | — | ||
| Q2 24 | $73.0B | $104.3B | ||
| Q1 24 | $72.5B | — |
负债/权益比ABTAZN
| Q4 25 | 0.25× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.30× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.3B | — |
| 自由现金流经营现金流 - 资本支出 | $2.6B | — |
| 自由现金流率自由现金流/营收 | 22.9% | — |
| 资本支出强度资本支出/营收 | 6.0% | — |
| 现金转化率经营现金流/净利润 | 1.87× | — |
| 过去12个月自由现金流最近4个季度 | $7.4B | — |
8季度趋势，按日历期对齐
经营现金流ABTAZN
| Q4 25 | $3.3B | — | ||
| Q3 25 | $2.8B | — | ||
| Q2 25 | $2.0B | — | ||
| Q1 25 | $1.4B | — | ||
| Q4 24 | $2.9B | — | ||
| Q3 24 | $2.7B | — | ||
| Q2 24 | $2.0B | — | ||
| Q1 24 | $1.0B | — |
自由现金流ABTAZN
| Q4 25 | $2.6B | — | ||
| Q3 25 | $2.3B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $933.0M | — | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | $2.1B | — | ||
| Q2 24 | $1.4B | — | ||
| Q1 24 | $627.0M | — |
自由现金流率ABTAZN
| Q4 25 | 22.9% | — | ||
| Q3 25 | 20.2% | — | ||
| Q2 25 | 13.9% | — | ||
| Q1 25 | 9.0% | — | ||
| Q4 24 | 19.6% | — | ||
| Q3 24 | 20.2% | — | ||
| Q2 24 | 13.8% | — | ||
| Q1 24 | 6.3% | — |
资本支出强度ABTAZN
| Q4 25 | 6.0% | — | ||
| Q3 25 | 4.4% | — | ||
| Q2 25 | 4.5% | — | ||
| Q1 25 | 4.7% | — | ||
| Q4 24 | 6.6% | — | ||
| Q3 24 | 5.2% | — | ||
| Q2 24 | 5.1% | — | ||
| Q1 24 | 4.0% | — |
现金转化率ABTAZN
| Q4 25 | 1.87× | — | ||
| Q3 25 | 1.70× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 1.64× | — | ||
| Q2 24 | 1.51× | — | ||
| Q1 24 | 0.84× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
